Company intelligence / Profile preview
Suzhou Bowei Biotechnology
Suzhou, Jiangsu Sheng, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Suzhou Bowei Biotechnology is a private Chinese biotech company focused on developing biological therapeutics, notably monoclonal antibodies. Its lead asset, EA5, is a humanized monoclonal antibody targeting complement system proteins for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). As of May 2025, EA5 is in Phase 1 clinical trials evaluating safety, pharmacokinetics, and pharmacodynamics in adult PNH patients. No published clinical results are available yet.
- Therapeutic areas
- OncologyImmunologyNeurologyHematology
- Modalities
- Monoclonal antibodyBiological products
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Suzhou Bowei Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Bowei Biotechnology.